This white paper provides insight into considerations when outsourcing Qualified Person for Pharmacovigilance (QPPV) services. It also touches upon potential challenges with oversight of the Marketing Authorization Holder (MAH) pharmacovigilance system.
Explore related content and topics

Pharmacovigilance & Patient Safety
We provide a comprehensive range of drug safety services, minimizing risk and protecting patient well-being from clinical development to…

Transparency and Reliability
Adjudication can be a tool to improve the confidence of trial data, although it is essential to have a clear and defined process. Historically,…

Literature Surveillance: Important Information About Patient Safety
Pharmaceutical companies must screen and analyze published literature from the clinical development stage through post-marketing as part of their…